Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China

Phase 1 Completed 44 enrolled AnewPharma Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With Advanced Solid Tumors.

Timeline

Start: 2013-05
Primary completion: 2014-10
Completion: 2016-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CM082	Unknown	—	Oral

Indications

No indication recorded.